Find Talbutal manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Lotusate, Profundol, 115-44-6, 5-allyl-5-sec-butylbarbituric acid, Talbutal [inn], Sec-butyl allyl barbituric acid
Molecular Formula
C11H16N2O3
Molecular Weight
224.26  g/mol
InChI Key
BJVVMKUXKQHWJK-UHFFFAOYSA-N
FDA UNII
4YIR8202AX

Talbutal
Talbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.
1 2D Structure

Talbutal

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
5-butan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
2.1.2 InChI
InChI=1S/C11H16N2O3/c1-4-6-11(7(3)5-2)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
2.1.3 InChI Key
BJVVMKUXKQHWJK-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCC(C)C1(C(=O)NC(=O)NC1=O)CC=C
2.2 Other Identifiers
2.2.1 UNII
4YIR8202AX
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 5-allyl-5-sec-butylbarbituric Acid

2. Allyl-sec-butyl-barbituric Acid

2.3.2 Depositor-Supplied Synonyms

1. Lotusate

2. Profundol

3. 115-44-6

4. 5-allyl-5-sec-butylbarbituric Acid

5. Talbutal [inn]

6. Sec-butyl Allyl Barbituric Acid

7. 5-allyl-5-(1-methylpropyl) Barbituric Acid

8. Win 5095

9. Talbutal (inn)

10. Barbituric Acid, 5-allyl-5-sec-butyl-

11. 5-(1-methylpropyl)-5-(2-propenyl)-2,4,6(1h,3h,5h)-pyrimidinetrione

12. 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-methylpropyl)-5-(2-propenyl)-

13. 4yir8202ax

14. Talbumalum

15. 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-methypropyl)-5-(2-propenyl)-

16. Talbutale [dcit]

17. Talbutale

18. Talbutalum

19. Talbutalum [inn-latin]

20. Lotusate (tn)

21. Hsdb 3397

22. Talbutal [usp:inn]

23. 5-butan-2-yl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione

24. Einecs 204-090-4

25. Unii-4yir8202ax

26. Latusate

27. Talbutal [hsdb]

28. Talbutal [mi]

29. Talbutal [vandf]

30. Talbutal Ciii(250 Mg)

31. Dsstox_cid_3630

32. Talbutal [mart.]

33. Talbutal [who-dd]

34. Dsstox_rid_97553

35. Dsstox_gsid_23630

36. Schembl122147

37. Talbutal [orange Book]

38. Chembl1200802

39. Dtxsid8023630

40. Chebi:134923

41. Tox21_113715

42. Hy-u00276

43. 5-(1-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1h,3h,5h)-trione

44. Cs-7222

45. Db00306

46. Ncgc00253567-01

47. Cas-115-44-6

48. Ft-0674795

49. D06887

50. Q409942

51. 5-allyl-5-(1-methylpropyl)-barbituric Acid

52. 5-allyl-5-sec-butyl-2,4,6(1h,3h,5h)-pyrimidinetrione

53. 5-allyl-5-sec-butylpyrimidine-2,4,6(1h,3h,5h)-trione

54. (rs)-5-allyl-5-sec-butylpyrimidine-2,4,6(1h,3h,5h)-trione

55. 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(1-methylpropyl)-5-(2-propen-1-yl)-

2.4 Create Date
2005-03-27
3 Chemical and Physical Properties
Molecular Weight 224.26 g/mol
Molecular Formula C11H16N2O3
XLogP31.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count3
Rotatable Bond Count4
Exact Mass224.11609238 g/mol
Monoisotopic Mass224.11609238 g/mol
Topological Polar Surface Area75.3 Ų
Heavy Atom Count16
Formal Charge0
Complexity329
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Therapeutic Uses

"SHORT- TO INTERMEDIATE-ACTING" COMPOUNDS ARE USED PRINCIPALLY AS SEDATIVE-HYPNOTIC AGENTS. /BARBITURATES, SHORT- TO INTERMEDIATE-ACTING/

Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 117


BARBITURATE WITH INTERMEDIATE DURATION OF ACTION. FOLLOWING USUAL HYPNOTIC DOSE, ONSET OF SLEEP OCCURS IN 15-30 MIN & LASTS FROM 6-8 HR. DOSE--USUAL HYPNOTIC, 120 MG BEFORE BEDTIME; SEDATIVE, 30 MG 2 OR 3 TIMES DAILY.

Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1003


BARBITURATES MAY BE USED FOR PREANESTHETIC MEDICATION & TO PRODUCE BASAL ANESTHESIA. ... BARBITURATES ARE EMPLOYED AS DIAGNOSTIC & THERAPEUTIC AIDS IN PSYCHIATRY, IN NARCOANALYSIS & NARCOTHERAPY. /BARBITURATES/

Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 119


The primary Medication Classification of the US Veterans Administration is CN301: Barbituric Acid Derivatives, Sedatives/Hypnotics.

United States Pharmacopeial Convention; USP dispensing Information 12th ed Vol IA p.573 (1992)


For more Therapeutic Uses (Complete) data for TALBUTAL (6 total), please visit the HSDB record page.


4.2 Drug Warning

EVALUATION OF EFFECTS OF GENERAL DEPRESSANTS ON FETUS & NEONATES IS DIFFICULT, & PLACE THAT BARBITURATES SHOULD OCCUPY IN OBSTETRICS IS STILL CONTROVERSIAL. /BARBITURATES/

Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 119


CAPACITY OF BARBITURATES TO INCR SYNTHESIS OF PORPHYRINS IS RESPONSIBLE FOR ONE ... BIZARRE & DANGEROUS SIDE EFFECT. IN PT SUFFERING FROM ACUTE INTERMITTENT PORPHYRIA, DRUGS MAY PPT SEVERE ATTACK, POSSIBLY ... PARALYSIS & DEATH. /BARBITURATES/

Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 111


WHEN RENAL FUNCTION IS IMPAIRED, BARBITURATES THAT DEPEND ON KIDNEY FOR ELIMINATION MAY CAUSE SEVERE CNS DEPRESSION & ... FURTHER REDUCE RENAL FUNCTION. ... UREMIA MAY INCR SENSITIVITY TO BARBITURATES ... /BARBITURATES/

Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 115


... CIRRHOTIC PT MAY SHOW INCR SENSITIVITY TO HYPNOTICS ... BARBITURATES SHOULD BE ADMIN WITH CAUTION, & INITIALLY IN REDUCED DOSES, TO PT WITH HEPATIC DAMAGE. ... SHOULD NOT BE ADMIN TO PT SHOWING PREMONITORY SIGNS OF HEPATIC COMA. /BARBITURATES/

Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 115


For more Drug Warnings (Complete) data for TALBUTAL (15 total), please visit the HSDB record page.


4.3 Drug Indication

For use as a sedative and hypnotic.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Talbutal is a short to intermediate-acting barbiturate that is a nonselective central nervous system (CNS) depressant. As with other barbiturates, talbutal is capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. Barbiturates may also induce anesthesia at sufficiently high therapeutic doses.


5.2 ATC Code

N - Nervous system

N05 - Psycholeptics

N05C - Hypnotics and sedatives

N05CA - Barbiturates, plain

N05CA07 - Talbutal


5.3 Absorption, Distribution and Excretion

THERE EXISTS NO IMPENETRABLE BARRIER TO DIFFUSION OF BARBITURATES IN BODY ... SMALL AMT ... MAY APPEAR IN MILK AFTER INGESTION OF LARGE DOSES. ... READILY CROSS PLACENTAL BARRIER, &, WITHIN FEW MIN AFTER INJECTION OF SHORT-... ACTING BARBITURATE, CONCN IN FETAL BLOOD APPROACHES THAT IN MATERNAL VENOUS BLOOD. /BARBITURATES/

Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 112


THREE MOST IMPORTANT FACTORS AFFECTING DISTRIBUTION & FATE OF BARBITURATES ARE LIPID SOLUBILITY ... PROTEIN BINDING, & EXTENT OF IONIZATION. ... THE MORE HIGHLY LIPID-SOL COMPD ARE SHORT-ACTING AGENTS... THEY TEND TO BE MORE RAPIDLY DEGRADED METABOLICALLY & ARE ALMOST COMPLETELY REABSORBED BY RENAL TUBULE. /BARBITURATES/

Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 113


For sedative hypnotic use, the barbiturates are usually administered orally. Such doses are rapidly and probably completely absorbed; sodium salts are absorbed more rapidly than the corresponding free acids, especially from liquid formulations. The onset of action varies from 10 to 60 min, depending upon the agent and the formulation, and is delayed by the presence of food in stomach. /Barbiturates/

Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 361


Barbiturates are distributed widely and readily cross the placenta. Binding to plasma proteins is a function of lipid solubility and is greatest for thiopental, which is bound to the extent of 65% or more. The highly lipid soluble barbiturates, led by those used to induce anesthesia, undergo redistribution after intravenous injection. Uptake into less vascular tissue, especially muscle and fat, leads to a decline in the concentration of barbiturate in the plasma and brain.

Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 361


Elimination/% excreted unchanged: renal/trace

United States Pharmacopeial Convention; USP Dispensing Information 12 th ed Vol IA p. 588 (1992)


5.4 Metabolism/Metabolites

MOST BARBITURATES ARE TRANSFORMED IN BODY TO INACTIVE METABOLITES. PRINCIPAL SITE OF BIOTRANSFORMATION IS LIVER. OXYBARBITURATES ARE TRANSFORMED ONLY BY LIVER; THIOBARBITURATES MAY BE TRANSFORMED TO SMALL EXTENT IN OTHER TISSUES, ESP KIDNEY & BRAIN ... /BARBITURATES/

Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 115


Hepatic biotransformation, primarily by the hepatic microsomal enzyme system. /Barbiturates/

United States Pharmacopeial Convention; USP Dispensing Information 12th ed Vol IA p.575 (1992)


With the exception of the less lipid-soluble aprobarbital and phenobarbital, nearly complete metabolism and/or conjugation of barbiturates in the liver precedes their renal excretion. The oxidation of radicals at C5 is the most important biotransformation responsible for termination of biological activity. Oxidation results in the formation of alcohols, kentones, phenols, or carboxylic acids, which may appear in the urine as such or as glucuronic acid conjugates. In some instances (e.g., phenobarbital), N-glucosylation is an important metabolic pathway. Other biotransformations include N-hydroxylation, desulfuration of thiobarbiturates to oxybarbiturates, opening of the barbituric acid ring, and N-dealkylation of N-alkylbarbiturates to active metabolites (e.g., mephobarbital to phenobarbital).

Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 361


5.5 Biological Half-Life

Half-life 15 hr

United States Pharmacopeial Convention; USP Dispensing Information 12 ed Vol. IA p. 588 (1992)


5.6 Mechanism of Action

Talbutal binds to GABAA receptors at a distinct binding site associated with a Cl- ionopore of the receptor. Upon binding, talbutal increases the duration of time for which the Cl- ionopore is open, leading to prolonged inhibitory effect of GABA at the postsynaptic thalamic neuron.


BARBITURATES REVERSIBLY DEPRESS ACTIVITY OF ALL EXCITABLE TISSUES. NOT ALL TISSUES ARE AFFECTED @ SAME DOSE OR CONCN; CNS IS EXQUISITELY SENSITIVE, SO THAT WHEN BARBITURATES ARE GIVEN IN SEDATIVE OR HYPNOTIC DOSES, VERY LITTLE EFFECT ON SKELETAL, CARDIAC, OR SMOOTH MUSCLE OCCURS. /BARBITURATES/

Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 104


... RETICULAR ACTIVATING SYSTEM IS EXQUISITELY SENSITIVE TO DEPRESSANT EFFECTS OF BARBITURATES ... WHATEVER ... EFFECTS OF BARBITURATES ELSEWHERE IN CNS, IT IS EFFECT ON RETICULAR SYSTEM THAT SEEMS TO BE RESPONSIBLE FOR INABILITY TO MAINTAIN WAKEFULNESS UNDER INFLUENCE OF BARBITURATE. /BARBITURATES/

Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 108


BARBITURATES ARE RESP DEPRESSANTS, AFFECTING BOTH DRIVE TO RESP & MECHANISM RESPONSIBLE FOR RHYTHMIC CHARACTER OF RESP MOVEMENT. /BARBITURATES/

Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 108


The mechanism(s) of action of the barbiturates is not completely known. Although the drugs act throughout the CNS, a site of particular sensitivity is the polysynaptic midbrain reticular formation which is concerned with the arousal mechanism. Barbiturates induce an imbalance in central inhibitory and facilitatory mechanisms influencing the cerebral cortex and the reticualar formation. The significance of the effect of barbiturates on neurotransmitters is unclear. It appears that the drugs decrease the excitability of both presynaptic and postsynaptic membranes. It has not been determined which of the various actions of barbiturates at cellular and synaptic levels are responsible for their sedative and hypnotic effects. /Barbiturates/

McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 1317


For more Mechanism of Action (Complete) data for TALBUTAL (9 total), please visit the HSDB record page.


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty